

October 27, 2022

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Intimation of Board Meeting

We wish to inform you that pursuant to Regulation 29 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, November 05, 2022, inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half-year ended September 30, 2022.

Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company’s Code of Conduct to regulate, monitor and report trading in securities of the Company by Designated Persons, the trading window for dealing in the securities of the Company has been closed from Saturday, October 01, 2022 until the expiry of 48 hours after the declaration of the standalone and consolidated unaudited financial results of the Company for the quarter and half-year ended September 30, 2022.

The aforesaid information is also being hosted on the Company’s website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

**Udayan
Shukla**

Digitally signed by
Udayan Shukla
Date: 2022.10.27
17:18:33 +05'30'

Udayan Shukla

(Compliance Officer)

Membership No.: F11744

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in